About the Company
diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DMAC News
DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. The company ...
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at DiaMedica Therapeutics Inc.'s ...
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a ...
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of ...
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
Diamedica Therapeutics (DMAC ... Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, NewAmsterdam Pharma Company, and Praxis Precision Medicines ...
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome ...
DiaMedica Therapeutics Inc DMAC
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript
DiaMedica Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen ...
DiaMedica Therapeutics Inc DMAC
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Q4 2023 DiaMedica Therapeutics Inc Earnings Call
Alexander Nowak; Analyst; Craig-Hallum Capital Group ...
Loading the latest forecasts...